Positive Data, Lease Agreements, and Product Launches Strengthen Portfolio - Research Report on Celldex, Teva, Health

 Positive Data, Lease Agreements, and Product Launches Strengthen Portfolio -
  Research Report on Celldex, Teva, Health Management, Perrigo, and Alnylam

PR Newswire

NEW YORK, July 5, 2013

NEW YORK, July 5, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Wall Street Reports announced new research reports highlighting Celldex
Therapeutics, Inc. (NASDAQ: CLDX), Teva Pharmaceutical Industries Ltd. (NYSE:
TEVA), Health Management Associates Inc. (NYSE: HMA), Perrigo Company (NYSE:
PRGO), and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY). Today's readers may
access these reports free of charge - including full price targets, industry
analysis and analyst ratings - via the links below.

Celldex Therapeutics, Inc. Research Report

On July 1, 2013, Celldex Therapeutics Inc. (Celldex) reported that the first
patient has been dosed in its pilot study of CDX-1135 (a soluble form of human
complement receptor type 1) in dense deposit disease (DDD). According to the
Company, DDD is an ultra-rare, progressive kidney disease that results in
kidney failure in the majority of affected individuals, and is caused by
dysregulation of the C3 Convertase, a major early component of the alternative
pathway of complement. J.H. Smith, M.D., said, "There are currently no
treatments and nearly half of all patients progress to end-stage renal disease
within 10 years of presentation, often spending the rest of their lives on
dialysis. In a mouse model of dense deposit disease, CDX-1135 has been shown
to control the abnormal complement activity and to reduce deposits in the
kidneys. We are optimistic that if we can control complement activation
earlier in the disease course and at a critical step in the complement
pathway, CDX-1135 may be able to restore kidney function and provide long term
disease control-a long-awaited outcome for patients, their families and
physicians." The Full Research Report on Celldex Therapeutics, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:


Teva Pharmaceutical Industries Ltd. Research Report

On July 1, 2013, Teva Pharmaceutical Industries Ltd. (Teva) announced that
data from the Glatiramer Acetate Low-frequency Administration (GALA) study,
which was published in the Annals of Neurology, show that a 40mg/ 1mL dose of
COPAXONE (glatiramer acetate injection) administered subcutaneously three
times per week significantly reduced relapse rates at 12 months and
demonstrated favorable safety and tolerability profile in patients with
relapsing-remitting multiple sclerosis (RRMS). Omar Khan, M.D., Professor of
Neurology and Chair of the Department of Neurology, Wayne State University
School of Medicine, Detroit, Michigan, said, "We are pleased with the positive
data of the GALA study which may lead to meaningful benefits for RRMS
patients. COPAXONE 40mg/ 1 mL given three times a week demonstrated a
favorable safety and tolerability profile, with the overall frequency of
adverse events comparable to those seen in the placebo group." At present, the
approved dose of COPAXONE is 20 mg/ 1mL, which is a once a day subcutaneous
injection. The Full Research Report on Teva Pharmaceutical Industries Ltd. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:


Health Management Associates Inc. Research Report

On June 26, 2013, Health Management Associates Inc. (Health Management)
announced that the Southeast Volusia Hospital District Board of Commissioners
chose it to start exclusive negotiations towards a lease agreement for the
112-bed Bert Fish Medical Center in New Smyrna Beach, Florida. Alan Levine,
Senior Vice President and Florida Group President for Health Management, said,
"Our mission at Health Management is to enable America's best local health
care, and we pledge to serve that mission at Bert Fish Medical Center."
According to Health Management, Bert Fish Medical Center will join its network
in Florida, which currently includes 23 hospitals and a statewide clinical
affiliation with the University of Florida's affiliated teaching hospital,
Shands Hospital. The Full Research Report on Health Management Associates Inc.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:


Perrigo Company Research Report

On July 2, 2013, Sergeant's Pet Care Products, Inc. (Sergeant's), a part of
Perrigo Company (Perrigo), reported the availability of Vetscription PetSTOP!
Behavior Correction Spray for Dogs and Cats at Wal-Mart stores nationwide.
Sergeant's stated that PetSTOP! Behavior Correction Spray helps modify
destructive or aggressive behavior by combining noise and a specifically
developed pheromone mist. The pheromone in the PetSTOP! Spray mimics a natural
pheromone that a mother dog or cat produces to calm and assure her young.
Further, Sergeant's stated that unlike other noise-making products that
produce a temporary effect, the spray's patent pending pheromone mist
redirects the pet's attention and behavior. The Full Research Report on
Perrigo Company - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:


Alnylam Pharmaceuticals, Inc. Research Report

On July 2, 2013, Alnylam Pharmaceuticals, Inc. (Alnylam) announced that it has
presented new pre-clinical data from its RNAi therapeutic program for the
treatment of hemophilia and rare bleeding disorders. Alnylam stated that the
new pre-clinical data demonstrate that ALN-AT3, a subcutaneously administered
RNAi therapeutic targeting antithrombin (AT), can normalize thrombin
generation and improve hemostasis in hemophilia mice and fully correct
thrombin generation in a non-human primate (NHP) hemophilia "inhibitor" model.
Akshay Vaishnaw, M.D., Ph.D., Executive Vice President and Chief Medical
Officer of Alnylam, said, "We are very excited by these new data with ALN-AT3
which demonstrate normalization of thrombin generation and improvement of
hemostasis in hemophilia models. Most importantly, we have demonstrated that
ALN-AT3 can fully correct thrombin generation in a non-human primate
hemophilia 'inhibitor' model, providing key proof of concept for our program."
The Company expects to file an investigational new drug application for
ALN-AT3 in mid-2013 and to initiate its Phase I study in late 2013. The Full
Research Report on Alnylam Pharmaceuticals, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.wsreports.com/r/full_research_report/5328_ALNY]



1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.


Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
Press spacebar to pause and continue. Press esc to stop.